• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Zydus Cadila receives final approval from USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

expresspharmaJuly 05, 2021

Tag: Zydus , Emtricitabine , Tenofovir , HIV

Zydus Cadila has received final approval from the USFDA to market Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg, a company statement said.

Zydus Cadila receives final approval from USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

The drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in one’s body so that the immune system can work better.

The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad. The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Previous:Adroit Biomed launches Glutone MD made from purest Setria Glutathione

Next:Bharat Biotech announces data from phase-III Covaxin clinical trials

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Zydus Cadila receives final approval from USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Tenofovir Alafenamide Fumarate (TAF)

Tenofovir Alafenamide Fumarate (TAF)
Chloromethyl isopropyl carbonate (CMIC, for Tenofovir)

Chloromethyl isopropyl carbonate (CMIC, for Tenofovir)
Tenofovir intermediates

Tenofovir intermediates
Tenofovir Disoproxil Fumarate Tablet

Tenofovir Disoproxil Fumarate Tablet
Tenofovir

Tenofovir
Tenofovir alafenamide fumarate

Tenofovir alafenamide fumarate
Tenofovir alafenamide

Tenofovir alafenamide
Tenofovir Disoproxil Fumarate

Tenofovir Disoproxil Fumarate
Tenofovir Alafenamide Fumarate

Tenofovir Alafenamide Fumarate
Tenofovir Alafenamide Fumarate API

Tenofovir Alafenamide Fumarate API

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service